Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]

Inclusion Criteria: Histologically/cytologically proven prostate adenocarcinoma Progression or non response with previous chemotherapy regimen (excluding Taxotere®) Received previous mitoxantrone/prednisone or one other chemotherapy regimen including emcyt +/- vinblastine Castration levels of testosterone (<50 ng/dL ) ECOG performance status 0-2 Laboratory requirements : Hematology: Neutrophils ≥ 1.5 x 10^9/L Hemoglobin > 10 g/dL (prior transfusion permitted). Platelets ≥ 100 x 10^9/L Hepatic function: Total bilirubin < the upper-normal limit of the institution. ALAT (SGPT) and ASAT (SGOT) ≤ 1.5 times the upper-normal limit of the institution. Renal function: Creatinine ≤1.5 times the upper normal limit (i.e., NCI grade ≤1) No severe or uncontrolled disease Exclusion Criteria Chemotherapy within the last 4 weeks Anti-androgen therapy within the last 4 weeks. Prior malignancy except the following: adequately treated non-melanomatous skin cancer and superficial bladder cancer from which the patient has been disease-free for >2 years. Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study screening. Treatment with any other anti-cancer therapy (except LHRH agonists) including any prescribed compounds and/or OTC products for the treatment of prostate cancer must be stopped prior to study entry. Other serious illness, psychiatric or medical condition that would not permit the patient to be managed according to the protocol including active uncontrolled infection and significant cardiac dysfunction.